The weight loss category has evolved dramatically over the past few decades, from meal replacement shakes in the ‘90s to fat burners, keto aids, and now the GLP-1 effect.
As GLP-1 drugs dominate headlines for their role in weight and appetite control, supplement developers are taking notice. Consumer interest in satiety, metabolic health, and glucose balance is surging which opens the door for functional ingredients to meet new demands. And this is just the beginning.
In the ‘90s, weight loss supplements were all about meal replacement shakes. By the 2000s, it was thermogenics and stimulants such as caffeine, ephedra, green tea extract. Then came appetite suppressants, keto aids, and blood sugar support formulas.
Now, we’re entering the GLP-1 era.
The U.S. weight loss supplement market is projected to more than double by 2030, growing from $8.5M to $17.9M (source). Consumer expectations are shifting toward appetite control, satiety, and metabolic health - all influenced by the popularity of GLP-1 receptor agonist drugs.
Unlike pharma, supplements must approach this trend strategically. As discussed in our webinar, brands can align with consumer interest without crossing regulatory lines. We’re seeing:
- Natural satiety ingredients like glucomannan and 5-HTP gain traction
- Interest in “GLP-1-like” botanicals like berberine and cinnamon
- A new market for products supporting GLP-1 drug users experiencing side effects like GI distress, nutrient gaps, and muscle loss
Do you have a question we could help answer? Are you exploring clinical or regulatory considerations? Contact us today and a member of our team will be in touch with you.
About the Author
|
Stephanie-Anne Girard, PhD |
